WVE WAVE Life Sciences

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company’s first quarter 2025 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: .

Analysts planning to participate during the Q&A portion of the live call can join the conference call by dialing (833) 630-1956 (domestic) or (412) 317-1837 (international).

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit and follow Wave on (formerly Twitter) and .

Contact:

Kate Rausch

VP, Corporate Affairs and Investor Relations

Investors:

Media:



EN
01/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Wave Life Sciences Reports Second Quarter 2025 Financial Results and P...

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 ...

Yun Zhong
  • Yun Zhong

AATD Multi-Dose Data Should Be Good; Could Be Available Soon

Initial INHBE data in 2H25 Will be the Next Catalyst. WVE expects to report safety and tolerability, as well as biomarker data that could reflect healthy weight loss from the placebo-controlled study (NCT06842186). We would expect positive stock reaction if the data show dose-dependent knockdown of

ResearchPool Subscriptions

Get the most out of your insights

Get in touch